Novo Nordisk partners with OpenAI in weight loss drug race
Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology across its operations as it looks to keep pace with rapid expansion in the obesity drug market. The Danish company announced in a statement on Tuesday that it would use AI to analyze complex datasets, identify promising drug candidates…
Original Source
Read the full article at Thehill →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.